The forecast for the import of blood-grouping reagents to the US indicates a steady upward trend, with imports projected to grow from $58.168 million in 2024 to $66.297 million in 2028. However, data from 2023 is not provided, which is essential for a complete year-on-year percentage variation analysis. The forecast demonstrates a consistent increase, suggesting positive growth in this sector.

Future trends to watch for include:

Advancements in medical technology, potentially increasing demand for blood-grouping reagents.
Regulatory changes that could impact the import process or costs.
The potential impact of global healthcare concerns, such as pandemics or supply chain disruptions, on import volumes and values.